The post MSTR falls 2.9% after S&P 500 snub, Robinhood makes the cut appeared on BitcoinEthereumNews.com. Journalist Posted: September 6, 2025 Key Takeaways MSTR may be included in the S&P 500 Index in December, according to analysts. Strategy downplayed the impact of Nasdaq’s capital-raising restrictions for crypto firms. Strategy (formerly MicroStrategy) stock, MSTR, was snubbed by the coveted S&P 500 Index, triggering a 2.9% price decline after market hours on the 5th of September. Instead, Robinhood beat MSTR to the index.   The market had anticipated that the leading Bitcoin corporate treasury holder would be included in the index, especially since it met all the necessary criteria. However, those expectations were disappointed, and as a result, MSTR dropped to $326 following the announcement. Source: Google Finance Will December favor MSTR? Some of the inclusion requirements for the equity index include massive liquidity depth and being profitable for the past four quarters.  But above all, the index’s ‘secret’ committee handling the inclusion process has the final say, noted a Bloomberg ETF analyst.  “Why wasn’t $MSTR allowed into the S&P 500 Index despite meeting all the criteria? Because the ‘Committee’ said no.” Now, some community members were pessimistic about MSTR’s chances of getting into the index during the next rebalancing window in December. But James Van Straten, a CoinDesk analyst, made a contrarian bet.  “December it is for MSTR, same setup as Tesla.” The inclusion would expand institutional investor interest and ETFs for MSTR. In response, Michael Saylor, Founder of Strategy, slammed the index in a subtle X (formerly Twitter) post, comparing MSTR vs S&P 500 Index (SPY) returns.  “Thinking about the S&P right now…” Source: X Both MSTR and BTC outperformed SPY on annualized returns, per the chart shared by Saylor.  Another hiccup for the firm was the recent Nasdaq proposal that some analysts claim may force crypto treasuries to get shareholders’ approval before raising capital. However, the… The post MSTR falls 2.9% after S&P 500 snub, Robinhood makes the cut appeared on BitcoinEthereumNews.com. Journalist Posted: September 6, 2025 Key Takeaways MSTR may be included in the S&P 500 Index in December, according to analysts. Strategy downplayed the impact of Nasdaq’s capital-raising restrictions for crypto firms. Strategy (formerly MicroStrategy) stock, MSTR, was snubbed by the coveted S&P 500 Index, triggering a 2.9% price decline after market hours on the 5th of September. Instead, Robinhood beat MSTR to the index.   The market had anticipated that the leading Bitcoin corporate treasury holder would be included in the index, especially since it met all the necessary criteria. However, those expectations were disappointed, and as a result, MSTR dropped to $326 following the announcement. Source: Google Finance Will December favor MSTR? Some of the inclusion requirements for the equity index include massive liquidity depth and being profitable for the past four quarters.  But above all, the index’s ‘secret’ committee handling the inclusion process has the final say, noted a Bloomberg ETF analyst.  “Why wasn’t $MSTR allowed into the S&P 500 Index despite meeting all the criteria? Because the ‘Committee’ said no.” Now, some community members were pessimistic about MSTR’s chances of getting into the index during the next rebalancing window in December. But James Van Straten, a CoinDesk analyst, made a contrarian bet.  “December it is for MSTR, same setup as Tesla.” The inclusion would expand institutional investor interest and ETFs for MSTR. In response, Michael Saylor, Founder of Strategy, slammed the index in a subtle X (formerly Twitter) post, comparing MSTR vs S&P 500 Index (SPY) returns.  “Thinking about the S&P right now…” Source: X Both MSTR and BTC outperformed SPY on annualized returns, per the chart shared by Saylor.  Another hiccup for the firm was the recent Nasdaq proposal that some analysts claim may force crypto treasuries to get shareholders’ approval before raising capital. However, the…

MSTR falls 2.9% after S&P 500 snub, Robinhood makes the cut

For feedback or concerns regarding this content, please contact us at [email protected]

Key Takeaways

MSTR may be included in the S&P 500 Index in December, according to analysts. Strategy downplayed the impact of Nasdaq’s capital-raising restrictions for crypto firms.


Strategy (formerly MicroStrategy) stock, MSTR, was snubbed by the coveted S&P 500 Index, triggering a 2.9% price decline after market hours on the 5th of September.

Instead, Robinhood beat MSTR to the index.  

The market had anticipated that the leading Bitcoin corporate treasury holder would be included in the index, especially since it met all the necessary criteria.

However, those expectations were disappointed, and as a result, MSTR dropped to $326 following the announcement.

Source: Google Finance

Will December favor MSTR?

Some of the inclusion requirements for the equity index include massive liquidity depth and being profitable for the past four quarters. 

But above all, the index’s ‘secret’ committee handling the inclusion process has the final say, noted a Bloomberg ETF analyst. 

Now, some community members were pessimistic about MSTR’s chances of getting into the index during the next rebalancing window in December. But James Van Straten, a CoinDesk analyst, made a contrarian bet

The inclusion would expand institutional investor interest and ETFs for MSTR.

In response, Michael Saylor, Founder of Strategy, slammed the index in a subtle X (formerly Twitter) post, comparing MSTR vs S&P 500 Index (SPY) returns. 

Source: X

Both MSTR and BTC outperformed SPY on annualized returns, per the chart shared by Saylor. 

Another hiccup for the firm was the recent Nasdaq proposal that some analysts claim may force crypto treasuries to get shareholders’ approval before raising capital.

However, the Strategy stated that the directive will not affect its capital plans. 

That said, Strategy’s BTC holdings hit 636,505 BTC after adding 4K BTC recently. Unlike the massive 21K BTC scooped in July, the buying spree has slowed significantly in the second part of Q3. 

Source: CryptoQuant

Next: ‘A new day at the SEC and CFTC’ – Is crypto’s turning point finally here?

Source: https://ambcrypto.com/mstr-falls-2-9-after-sp-500-snub-robinhood-makes-the-cut/

Market Opportunity
Threshold Logo
Threshold Price(T)
$0.006506
$0.006506$0.006506
-1.22%
USD
Threshold (T) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09